Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Canagliflozin/Placebo Placebo/Canagliflozin Clear all
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

NCT02025907
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

CANVAS - CANagliflozin cardioVascular Assessment Study

NCT01032629
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
Interventions
Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
58
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

NCT01081834
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Placebo, Sitagliptin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

NCT00650806
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
35
States / cities
Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

NCT03136484
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Semaglutide, Canagliflozin, Placebo (canagliflozin), Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
57
States / cities
Anaheim, California • La Mesa, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 10, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

NCT02053116
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

NCT01177163
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Weight Loss With SGLT2 Inhibition

NCT02360774
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

NCT01989754
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Albuminuria
Interventions
Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
5,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

NCT01787357
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 10, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

NCT01340664
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 50 mg, Placebo, Canagliflozin 150 mg, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Little Rock, Arkansas • National City, California • Spring Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 10, 2026, 9:59 AM EDT